217 related articles for article (PubMed ID: 19334379)
1. [In vitro activity of linezolid/ertapenem combination in resistant gram-positive bacteria].
Eraç B; Taşli H; Ermertcan S; Cilli F; Limoncu MH
Mikrobiyol Bul; 2009 Jan; 43(1):45-51. PubMed ID: 19334379
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
[TBL] [Abstract][Full Text] [Related]
3. [In vitro susceptibility to linezolid in methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus strains].
Efe S; Sinirtaş M; Ozakin C
Mikrobiyol Bul; 2009 Oct; 43(4):639-43. PubMed ID: 20084917
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
5. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
Ross JE; Anderegg TR; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 May; 52(1):53-8. PubMed ID: 15878443
[TBL] [Abstract][Full Text] [Related]
6. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Gaona Álvarez C; Sánchez Silos RM; Hernández Rastrollo R; Martínez Tallo E; Cordero Carrasco JL
Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods.
Jacqueline C; Caillon J; Le Mabecque V; Miegeville AF; Donnio PY; Bugnon D; Potel G
J Antimicrob Chemother; 2003 Apr; 51(4):857-64. PubMed ID: 12654769
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1beta-methylcarbapenems with potent activities against multiresistant gram-positive bacteria.
Ueda Y; Sunagawa M
Antimicrob Agents Chemother; 2003 Aug; 47(8):2471-80. PubMed ID: 12878507
[TBL] [Abstract][Full Text] [Related]
10. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
11. In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2 μg/mL (VA2-MRSA).
Tang HJ; Chen CC; Ko WC; Yu WL; Chiang SR; Chuang YC
Int J Antimicrob Agents; 2011 Jul; 38(1):46-51. PubMed ID: 21549575
[TBL] [Abstract][Full Text] [Related]
12. Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods.
Muller-Serieys C; Drugeon HB; Etienne J; Lascols C; Leclercq R; Nguyen J; Soussy CJ
Clin Microbiol Infect; 2004 Mar; 10(3):242-6. PubMed ID: 15008946
[TBL] [Abstract][Full Text] [Related]
13. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):199-209. PubMed ID: 17908617
[TBL] [Abstract][Full Text] [Related]
14. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid.
Wareham DW; Abbas H; Karcher AM; Das SS
J Infect; 2006 Apr; 52(4):300-4. PubMed ID: 16099052
[TBL] [Abstract][Full Text] [Related]
15. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients.
Gonzalez N; Sevillano D; Alou L; Cafini F; Gimenez MJ; Gomez-Lus ML; Prieto J; Aguilar L
J Antimicrob Chemother; 2013 Oct; 68(10):2291-5. PubMed ID: 23674766
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus.
Jacqueline C; Caillon J; Grossi O; Le Mabecque V; Miegeville AF; Bugnon D; Batard E; Potel G
Antimicrob Agents Chemother; 2006 Jul; 50(7):2547-9. PubMed ID: 16801442
[TBL] [Abstract][Full Text] [Related]
17. Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Gunderson BW; Ibrahim KH; Peloquin CA; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 2003 Jan; 47(1):398-9. PubMed ID: 12499223
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of linezolid and tigecycline against methicillin-resistant Staphylococcus aureus strains.
Kaya O; Akcam FZ; Temel EN
Microb Drug Resist; 2008 Jun; 14(2):151-3. PubMed ID: 18494600
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.
Jacqueline C; Navas D; Batard E; Miegeville AF; Le Mabecque V; Kergueris MF; Bugnon D; Potel G; Caillon J
Antimicrob Agents Chemother; 2005 Jan; 49(1):45-51. PubMed ID: 15616274
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway.
Simonsen GS; Bergh K; Bevanger L; Digranes A; Gaustad P; Melby KK; Høiby EA
Scand J Infect Dis; 2004; 36(4):254-8. PubMed ID: 15198180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
